Drug Trial Radar · NCT03088540
Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
712
Actual
Start
May 29, 2017
Primary completion
Apr 18, 2025
Study completion Apr 18, 2025
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- Collaborators
- Sanofi
- First posted
- Mar 23, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objectives of the study are: * To compare the overall survival (OS) of cemiplimab versus standard-of-care platinum-based chemotherapies in the first-line treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 in ≥50% of tumor cells * To compare the progression-free survival (PFS) of cemiplimab versus standard-of-care platinum-based chemotherapies in the first-line treatment of patients with advanced or metastatic NSCLC whose tumors express PD-L1 in ≥50% of tumor cells The key secondary objective of the study is to compare the objective response rate (ORR) of cemiplimab versus platinum-based chemotherapies
Conditions
- Carcinoma,Non-Small-Cell Lung
- Lung Carcinomas, Non-Small-Cell
- Non-small-cell Lung Carcinoma
- Nonsmall Cell Lung Cancer
Interventions
PemetrexedDrug
Patients will be administered pemetrexed chemotherapy as per protocol with either cisplatin or carboplatin
PaclitaxelDrug
Patients will be administered paclitaxel chemotherapy as per protocol with either cisplatin or carboplatin
GemcitabineDrug
Patients will be administered gemcitabine chemotherapy as per protocol with either cisplatin or carboplatin
CisplatinDrug
Administered with either Pemetrexed, Paclitaxel or gemcitabine.
CarboplatinDrug
Administered with either Pemetrexed, Paclitaxel or gemcitabine.
cemiplimabDrug
Patients will be administered cemiplimab as per protocol.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: Up to 94 months
- Progression-free Survival (PFS) Per Blinded IRCTime frame: Up to 94 months
Locations
192 sites in 24 countries. Site status is shown where the registry gives one.
Clinical Study Site
Fitzroy, Australia
Clinical Study Site
Albury, New South Wales, Australia
Clinical Study Site
Wollongong, New South Wales, Australia
Clinical Study Site
Minsk, Belarus
Clinical Study Site
Mogilev, Belarus
Clinical Study Site
Barretos, Brazil
Clinical Study Site
Curitiba, Brazil
Clinical Study Site
Joinville, Brazil
Clinical Study Site
Lajeado, Brazil
Clinical Study Site
Mogi das Cruzes, Brazil
Clinical Study Site
Passo Fundo, Brazil
Clinical Study Site
Pelotas, Brazil
Clinical Study Site 2
Porto Alegre, Brazil
Clinical Study Site 3
Porto Alegre, Brazil
Clinical Study Site
Recife, Brazil
Clinical Study Site
Rio de Janeiro, Brazil
Clinical Study Site
Salvador, Brazil
Clinical Study Site
Santa Cecília, Brazil
Clinical Study Site
São José do Rio Preto, Brazil
Clinical Study Site #3
São Paulo, Brazil
Clinical Study Site #4
São Paulo, Brazil
Clinical Study Site 1
São Paulo, Brazil
Clinical Study Site 2
São Paulo, Brazil
Clinical Study Site 1
Porto Alegre, Rio Grande do Sul, Brazil
Clinical Study Site
Dobrich, Bulgaria
Clinical Study Site
Gabrovo, Bulgaria
Clinical Study Site
Recoleta, Chile
Clinical Study Site
Santiago, Chile
Clinical Study Site
Temuco, Chile
Clincial Study Site
Viña del Mar, Chile
Clinical Study Site
Guangdong, China
Clinical Study Site
Harbin, China
Clinical Study Site
Linyi, China
Clinical Study Site 1
Shanghai, China
Clinical Study Site 2
Shanghai, China
Clinical Study Site 1
Tianjin, China
Clinical Study Site 2
Tianjin, China
Clinical Study Site
Xuzhou, China
Clinical Study Site
Zhejiang, China
Clinical Study Site
Lanshan, Shandong, China
Showing 40 of 192 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.